Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ONCS Alert Alert! 3 Phases II with oncology studies!
$ONCS Bullish Pattern! Strong Volume!
$ONCS Cancer Electroporation Up with volume good .
$ONCS Runner Stock Of The Year!
$ONCS Asco 2013 stock! Strong accumulation!!!
$ONCS Brutal volume. Multibagger Stock!
ONCS Breakout Alert! PT $1! ASCO 2013 $ONCS Breakout Alert! PT $1! ASCO 2013 stock
$ONCS Breakout Alert! PT $1! ASCO 2013 stock
$ONCS $0.232 in beast mode!
https://twitter.com/inversbio/status/314316562733613056/photo/1
$ONCS in beast mode!
https://twitter.com/inversbio/status/314316562733613056/photo/1
BLA BLA BLA in AVEW. 2 years with comments and zero company....
ILNS Only 304k shares in $0.011 - Up +11.11%! Company with Alzheimer studies in phase II.
ILNS Only 184k shares in $0.011 - Up +11.11%
ILNS 11.11% $0.011 Alzheimer studies in phase II
ILNS 11.11% $0.011 Alzheimer studies in phase II
ILNS Alert! Alert! Breakout $0.011! Biotech Stock with Alzheimer's studies!
ILNS Alert! Alert! Breakout $0.011! Biotech Stock with Alzheimer's studies!
ILNS $0.011 Breakout ALERT!
For future Investors in AVEW - READ FIRST -
You can see that Joe Wooten is still the president of the company. Traveller Brothers continue with the company. You do not be fooled. Now nothing has changed in AVEW. They just changed the name ONLY.
Nevada ONLY SOS Change: http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=cqEh1c%252bAgprdv%252fCYUk0lwg%253d%253d
Nothing. The company remains the same. You can see that there is no buy positions. It is a typical strategy of this managers..(Wooten & Traveller brothers?). Ridiculous... IMHO.
OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
SAN DIEGO, March 25, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCQB: ONCS) – a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors – announced positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial. The data was presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference on March 22, in New York City.
(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)
In this analysis, all melanoma lesions that demonstrated at least a partial or complete response (PR or CR) to treatment with ImmunoPulse were followed, to determine durable response. Sixty-eight percent and forty-five percent of treated lesions demonstrated a durable response at three and six months, respectively.
Punit Dhillon, President and CEO said, "We are encouraged by this updated data from the interim analysis, especially in light of recent announcements related to durability of response for other intralesional therapies. This data not only shows that ImmunoPulse can effectively eliminate the targeted tumors but also that our treatment can have a lasting effect on those tumors."
Adil Daud, MD – the study's principal investigator at the University of California San Francisco – said, "This data demonstrates that the lesions we have selected for treatment are responding well to the therapy and that the ImmunoPulse can trigger a lasting immune response, against the treated lesion. It is now important for us to see if this local immune reaction can result in a more widespread response against untreated lesions."
These interim results reinforce previously announced Phase I data demonstrating that ImmunoPulse therapy is safe and well tolerated, as well as producing robust objective response rates, in patients with metastatic melanoma. OncoSec expects to complete enrollment of approximately 25 patients in total, in Q2 2013, with final analysis anticipated in Q4 2013.
About the Phase II ImmunoPulse Study
A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response, following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation, with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8, with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years, for safety.
About Melanoma
Melanoma is the most serious form of skin cancer. If it is recognized and treated early, it is almost always curable but, if it is not, the cancer can advance and spread to other parts of the body where it becomes hard to treat and can be fatal. While it is not the most common of the skin cancers, it causes the most deaths. The American Cancer Society estimates that, at present, about 123,000 new cases of melanoma in the US are diagnosed in a year; resulting in approximately 10,000 deaths. Melanoma originates in melanocytes: the cells that produce the pigment melanin that colors our skin, hair, and eyes. The majority of melanomas are black or brown but can also often be skin-colored, pink, red, purple, blue or white. Currently, there remain few treatment options for patients with late-stage metastatic disease that can extend survival for the broad population.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy, to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers, using these powerful and targeted anti-cancer agents, has demonstrated selective destruction of cancerous cells – while sparing healthy normal tissues – during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse, targeting lethal skin cancers. More information is available at http://www.oncosec.com/.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Incorporated
AMGN ONCS Recent Melanoma Trial Data Has Biotech Stocks Moving
Melanoma is known by experts to be the deadliest form of skin cancer. Melanoma is curable, but only if it is detected and treated early on. According to the American Cancer Society, nearly 123,000 new cases of melanoma are diagnosed in the U.S. each year, resulting in 10,000 deaths. There are very few treatment options out there for patients with late-stage metastatic cancer that can increase survival rates and time periods. I will discuss two of these options below and compare them to see which offers more promising results.
Amgen (AMGN) recently announced positive results from its phase 3 clinical trial of Talimogene Laherparepvec (TVEC), a cancer drug candidate that targets melanoma. The drug met its primary endpoint in the trial which evaluated the drug's safety and efficacy in fighting later stages of melanoma against subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). TVEC was found to lead to a complete or partial response lasting for six months or more. The drug candidate had a "durable response rate" (DRR) of 16% in patients treated with TVEC, compared to a durable response rate of 2% in patients treated with GM-CSF. A separate interim analysis also favored TVEC over GM-CSF.
TVEC is injected directly into tumors. Once inside the tumor, it goes through selective replication, which causes the cancer cell membrane to burst. The ruptured cancer cells then releases the replicated viruses held inside. These viruses travel to other tumor cells and invade them. The process stops once the weakened virus encounters healthy cells. During the process, TVEC also initiates the production of a white blood cell growth factor within the tumor, which is required for an immune response.
Since the release of the trial data Amgen has traded higher by 6%, as the encouraging news has been well received by Wall Street. The company has one of the highest EPS figures in the industry at $5.52 and has been a strong growth investment for many, since it was a developmental biotech.
OncoSec Medical (ONCS.OB) is developing its two advanced stage treatments, ImmunoPulse DNA-based immunotherapy and NeoPulse therapy, which are used to treat solid tumors. The company recently announced durable response results from its phase 2 metastatic melanoma trial in its update of interim preliminary data. Treated lesions that demonstrated a partial or complete response were followed to determine durable response rate after being treated with ImmunoPulse. Impressively, 81% of treated lesions showed a partial or complete response at Day 39. And 68% of treated lesions showed a durable response at three months, while 45% of treated lesions showed a durable response at six months. This translated into 69% of patients showing a durable response of their treated lesions at three months, compared to 38% at six months.
OncoSec Medical's ImmunoPulse therapy is superior to Amgen's TVEC candidate. While TVEC had a durable response rate of 16% for six months, ImmunoPulse had a durable response rate of 38% at six months. Just as an added reference, Vical's (VICL) Allovectin had a response rate of 12% in its phase 2 trial. The announcement for the completion of enrollment in the second quarter and a final analysis is expected in the fourth quarter of 2013. Based on its durability, cost and treatment cycle, treatment of skin cancer through OncoSec's ImmunoPulse therapy is a superior option compared to Amgen's TVEC.
In November 2012, OncoSec announced interim analysis of the first thirteen subjects enrolled in a phase 2 study. NeoPulse, OncoSec Medical's other therapy used to treat solid tumors, also appears to have better results compared to surgical resection. A key advantage of this approach appears to be less damage to normal healthy tissues along with improved cosmetics. In addition, should OncoSec remain on track, the technique should require less or no need for reconstructive applications. As it further reduces the cost associated with hospitalization for extensive reconstruction, the approach warrants further exploration as an alternative in select cases of skin cancer.
A total of up to 25 patients with stage 3 or 4 skin cancer/melanoma will be enrolled in this phase 2, single-arm, open-label and multi-center study. The trial is being conducted to analyze local and distant objective response that would follow the treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation, with the most important outcome of this treatment in twenty four weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.
OncoSec had traded higher by as much as 10% following the data presentation at the HemOnc Today conference and saw its volume increase significantly. The company looks to have a cash position strong enough to carry it through the next 18 months and through the completion of the trial.
In summary, OncoSec Medical's Immunotherapy appears to be a superior option for treating metastatic melanoma, with best in class results. The durable response rate for ImmunoPulse is higher for both three months and six months compared to Amgen's TVEC. In addition, the essential features of ImmunoPulse therapy are not restricted to melanoma only. It is also useful in treating patients suffering from T-cell Lymphoma due to its safety and long-term benefits. Electroporation, which is OncoSec Medical's core technology used in its two delivery platforms, is a more beneficial delivery choice due to the increased transfection of agents, and also avoids issues of immunogenicity that is seen in a viral delivery approach. In addition, interleukin-12 (IL-12) cytokine, which is used in the ImmunoPulse therapy, is a naturally occurring protein that activates and boosts levels of macrophages and T-cells. IL-12 has been shown to be a very effective immune-modulator in cancer therapy. IL-12 is thought to activate the immune system by re-educating the immune response in the tumor microenvironment. IL-12, when introduced into the local tumor microenvironment, can significantly alter the immunosuppressive state in the tumor microenvironment to make it inflammatory and destructive to the tumor. While the approach is similar to TVEC, no lingering virus remains floating throughout the body until the healthy cells have controlled it.
Amgen will be to market before OncoSec, with its treatment for the unmet needs of those that suffer from melanoma. However, OncoSec has the ability to supersede the TVEC approach, based on clinical results superiority. Both companies offer investors tremendous growth opportunity.
Source: http://seekingalpha.com/article/1302841-recent-melanoma-trial-data-has-biotech-stocks-moving
AMGN ONCS Recent Melanoma Trial Data Has Biotech Stocks Moving
Melanoma is known by experts to be the deadliest form of skin cancer. Melanoma is curable, but only if it is detected and treated early on. According to the American Cancer Society, nearly 123,000 new cases of melanoma are diagnosed in the U.S. each year, resulting in 10,000 deaths. There are very few treatment options out there for patients with late-stage metastatic cancer that can increase survival rates and time periods. I will discuss two of these options below and compare them to see which offers more promising results.
Amgen (AMGN) recently announced positive results from its phase 3 clinical trial of Talimogene Laherparepvec (TVEC), a cancer drug candidate that targets melanoma. The drug met its primary endpoint in the trial which evaluated the drug's safety and efficacy in fighting later stages of melanoma against subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). TVEC was found to lead to a complete or partial response lasting for six months or more. The drug candidate had a "durable response rate" (DRR) of 16% in patients treated with TVEC, compared to a durable response rate of 2% in patients treated with GM-CSF. A separate interim analysis also favored TVEC over GM-CSF.
TVEC is injected directly into tumors. Once inside the tumor, it goes through selective replication, which causes the cancer cell membrane to burst. The ruptured cancer cells then releases the replicated viruses held inside. These viruses travel to other tumor cells and invade them. The process stops once the weakened virus encounters healthy cells. During the process, TVEC also initiates the production of a white blood cell growth factor within the tumor, which is required for an immune response.
Since the release of the trial data Amgen has traded higher by 6%, as the encouraging news has been well received by Wall Street. The company has one of the highest EPS figures in the industry at $5.52 and has been a strong growth investment for many, since it was a developmental biotech.
OncoSec Medical (ONCS.OB) is developing its two advanced stage treatments, ImmunoPulse DNA-based immunotherapy and NeoPulse therapy, which are used to treat solid tumors. The company recently announced durable response results from its phase 2 metastatic melanoma trial in its update of interim preliminary data. Treated lesions that demonstrated a partial or complete response were followed to determine durable response rate after being treated with ImmunoPulse. Impressively, 81% of treated lesions showed a partial or complete response at Day 39. And 68% of treated lesions showed a durable response at three months, while 45% of treated lesions showed a durable response at six months. This translated into 69% of patients showing a durable response of their treated lesions at three months, compared to 38% at six months.
OncoSec Medical's ImmunoPulse therapy is superior to Amgen's TVEC candidate. While TVEC had a durable response rate of 16% for six months, ImmunoPulse had a durable response rate of 38% at six months. Just as an added reference, Vical's (VICL) Allovectin had a response rate of 12% in its phase 2 trial. The announcement for the completion of enrollment in the second quarter and a final analysis is expected in the fourth quarter of 2013. Based on its durability, cost and treatment cycle, treatment of skin cancer through OncoSec's ImmunoPulse therapy is a superior option compared to Amgen's TVEC.
In November 2012, OncoSec announced interim analysis of the first thirteen subjects enrolled in a phase 2 study. NeoPulse, OncoSec Medical's other therapy used to treat solid tumors, also appears to have better results compared to surgical resection. A key advantage of this approach appears to be less damage to normal healthy tissues along with improved cosmetics. In addition, should OncoSec remain on track, the technique should require less or no need for reconstructive applications. As it further reduces the cost associated with hospitalization for extensive reconstruction, the approach warrants further exploration as an alternative in select cases of skin cancer.
A total of up to 25 patients with stage 3 or 4 skin cancer/melanoma will be enrolled in this phase 2, single-arm, open-label and multi-center study. The trial is being conducted to analyze local and distant objective response that would follow the treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation, with the most important outcome of this treatment in twenty four weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.
OncoSec had traded higher by as much as 10% following the data presentation at the HemOnc Today conference and saw its volume increase significantly. The company looks to have a cash position strong enough to carry it through the next 18 months and through the completion of the trial.
In summary, OncoSec Medical's Immunotherapy appears to be a superior option for treating metastatic melanoma, with best in class results. The durable response rate for ImmunoPulse is higher for both three months and six months compared to Amgen's TVEC. In addition, the essential features of ImmunoPulse therapy are not restricted to melanoma only. It is also useful in treating patients suffering from T-cell Lymphoma due to its safety and long-term benefits. Electroporation, which is OncoSec Medical's core technology used in its two delivery platforms, is a more beneficial delivery choice due to the increased transfection of agents, and also avoids issues of immunogenicity that is seen in a viral delivery approach. In addition, interleukin-12 (IL-12) cytokine, which is used in the ImmunoPulse therapy, is a naturally occurring protein that activates and boosts levels of macrophages and T-cells. IL-12 has been shown to be a very effective immune-modulator in cancer therapy. IL-12 is thought to activate the immune system by re-educating the immune response in the tumor microenvironment. IL-12, when introduced into the local tumor microenvironment, can significantly alter the immunosuppressive state in the tumor microenvironment to make it inflammatory and destructive to the tumor. While the approach is similar to TVEC, no lingering virus remains floating throughout the body until the healthy cells have controlled it.
Amgen will be to market before OncoSec, with its treatment for the unmet needs of those that suffer from melanoma. However, OncoSec has the ability to supersede the TVEC approach, based on clinical results superiority. Both companies offer investors tremendous growth opportunity.
Source: http://seekingalpha.com/article/1302841-recent-melanoma-trial-data-has-biotech-stocks-moving
If Joe wants this stock will go to $0.10 but, Does he want to? imo.
Where is MOMO effect? 1 only PR and $14k in yesterday volume? I don't see in this moment MOMO... imo.
And I hold AVEW shares.
I do not think it is not joe. They act in the same way. They do not buy a single share. Imo.
Bur, Joe Wooten like past a penny? Or only like cash dilution machine without serious MOMO? This is the questions... IMHO.
We need a big MOMO imho. With big MOMO go to $0.10 or more...
0 news today? They continue in AVEW. Typical formula of Joe Wooten. 1 new and zero more news... for last six month... IMO. R/S innevitable
Ask in 0,0002!!!
AVEW - similar alert that SKTO...
Nice day! On watch ARRY
Good day in NEOM. Imo
22 c this morning. I am preparing saint holidays! How are in USA?
Good morning, no priblem my friend
Vista Partners Initiates Coverage on OncoSec Medical Inc.; Target Price $2.90.
SAN FRANCISCO, May 26, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage of OncoSec Medical Inc. (OTCBB: ONCS) ("the Company") with a twelve month target price of $2.90. Ross Silver, Principal Analyst at Vista Partners stated, "OncoSec's ElectroOncology clinical development pipeline is comprised of cancer treatments intended to address therapeutic needs in multi-billion dollar markets. The company's ElectroChemotherapy has shown in clinical trials to date that it selectively destroys cancer cells while leaving healthy tissue intact, dramatically improving patient quality of life. This provides OncoSec with a considerable potential competitive advantage compared to existing treatment options." Mr. Silver concludes, "OncoSec's ElectroImmunotherapy could prove to be a powerful new approach to treat local and metastatic tumors."
To download a FREE copy of the OncoSec Medical Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. Vista Partners LLC is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.
Contact: 877.215.4813 or info@vistapglobal.com
SOURCE Vista Partners
OncoSec Medical (ONCS) Targets $47 Billion Cancer Market
NEW YORK, NY--(Marketwire - Mar 5, 2012) - Investment Opinion highlighting Dendreon Corp. (NASDAQ: DNDN), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), and OncoSec Medical, Inc. (OTCBB: ONCS). OncoSec Medical, a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic diseases, recently announced that the company has been highlighted in the March issue of Medical Device & Diagnostic Industry (MDDI) outlining development of its technology platform for treatment of rare and deadly skin cancers.
OncoSec uses electroporation which dramatically facilitates the ability of chemotherapy drugs to penetrate the cell, reducing the amount of drugs needed for treatment while increasing the effectiveness. At $47.7 billion, cancer is one of the largest and fastest growing markets in the medical industry and OncoSec is becoming a leading innovator in the fight against metastatic melanoma and Merkel cell carcinoma with the company's promising OMS ElectroOncology treatment platform.
Punit Dhillon, President and CEO of OncoSec, stated, "The treatment approach is potent. We can see a 4,000 to 10,000 fold increase in the movement of the agent into the cell." Substantially increasing the cellular uptake of chosen therapeutic agents can minimize the dose required to destroy cancer cells and spare healthy tissues. In addition, by enhancing the delivery mechanism of treatment, the side effects of non-targeted cancer-treatment protocols such as traditional chemotherapy can be drastically reduced.
Last week, Dendreon Corp. announced new executive appointments, Ariad Pharmaceuticals reported its 2011 financial results, and Onyx Pharmaceuticals completed the enrollment of phase 3 trials for the potential treatment of relapsed myeloma. The MDDI article highlights OncoSec as having the potential to push electroporation to the forefront of cancer treatment. The article also notes the company's upcoming milestones for 2012. Select the link to view the entire article on OncoSec Medical Incorporated:
http://www.mddionline.com/article/oncoSec-could-revolutionize-oncology-therapy
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Capital News Circuit twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.
Source: http://www.marketwire.com/press-release/oncosec-medical-oncs-targets-47-billion-cancer-market-1627661.htm
AVEW Next Gold Metal Penny Stock!
AVEW Volume Alert! SHORT SQUEEZE!